News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
738,749 Results
Type
Article (43719)
Company Profile (473)
Press Release (694545)
Multimedia
Podcasts (124)
Webinars (20)
Section
Business (209328)
Career Advice (2041)
Deals (36153)
Drug Delivery (120)
Drug Development (83977)
Employer Resources (174)
FDA (16699)
Job Trends (15191)
News (354188)
Policy (33283)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2659)
Accelerated approval (37)
Adcomms (28)
Allergies (147)
Alliances (51111)
ALS (179)
Alzheimer's disease (1737)
Antibody-drug conjugate (ADC) (335)
Approvals (16942)
Artificial intelligence (552)
Autoimmune disease (166)
Automation (41)
Bankruptcy (373)
Best Places to Work (11840)
BIOSECURE Act (20)
Biosimilars (196)
Biotechnology (331)
Bladder cancer (163)
Brain cancer (61)
Breast cancer (656)
Cancer (4983)
Cardiovascular disease (425)
Career advice (1726)
Career pathing (38)
CAR-T (295)
CDC (47)
Celiac Disease (2)
Cell therapy (789)
Cervical cancer (36)
Clinical research (71503)
Collaboration (1819)
Company closure (4)
Compensation (1195)
Complete response letters (67)
COVID-19 (2775)
CRISPR (102)
C-suite (904)
Cystic fibrosis (152)
Data (6381)
Decentralized trials (2)
Denatured (40)
Depression (145)
Diabetes (507)
Diagnostics (6767)
Digital health (50)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (272)
Drug pricing (196)
Drug shortages (29)
Duchenne muscular dystrophy (247)
Earnings (91529)
Editorial (61)
Employer branding (21)
Employer resources (153)
Events (121134)
Executive appointments (1015)
FDA (19885)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (11)
Frontotemporal dementia (24)
Funding (1548)
Gene editing (218)
Generative AI (45)
Gene therapy (651)
GLP-1 (1013)
Government (4765)
Grass and pollen (6)
Guidances (385)
Healthcare (19212)
HIV (64)
Huntington's disease (47)
IgA nephropathy (87)
Immunology and inflammation (280)
Immuno-oncology (63)
Indications (117)
Infectious disease (3056)
Inflammatory bowel disease (202)
Inflation Reduction Act (17)
Influenza (122)
Intellectual property (259)
Interviews (316)
IPO (16933)
IRA (53)
Job creations (3714)
Job search strategy (1440)
JPM (66)
Kidney cancer (16)
Labor market (86)
Layoffs (582)
Leadership (34)
Legal (8028)
Liver cancer (93)
Longevity (14)
Lung cancer (674)
Lymphoma (385)
Machine learning (43)
Management (59)
Manufacturing (828)
MASH (172)
Medical device (13929)
Medtech (13984)
Mergers & acquisitions (20306)
Metabolic disorders (1329)
Multiple sclerosis (168)
NASH (19)
Neurodegenerative disease (346)
Neuropsychiatric disorders (97)
Neuroscience (3046)
Neurotech (1)
NextGen: Class of 2026 (6770)
Non-profit (4586)
Now hiring (68)
Obesity (638)
Opinion (286)
Ovarian cancer (169)
Pain (205)
Pancreatic cancer (236)
Parkinson's disease (298)
Partnered (34)
Patents (511)
Patient recruitment (511)
Peanut (57)
People (60360)
Pharmaceutical (85)
Pharmacy benefit managers (30)
Phase 1 (22488)
Phase 2 (31525)
Phase 3 (23303)
Pipeline (5486)
Policy (301)
Postmarket research (2602)
Preclinical (9613)
Press Release (67)
Prostate cancer (247)
Psychedelics (56)
Radiopharmaceuticals (303)
Rare diseases (907)
Real estate (6065)
Recruiting (71)
Regulatory (25064)
Reports (53)
Research institute (2490)
Resumes & cover letters (354)
Rett syndrome (27)
RNA editing (21)
RSV (80)
Schizophrenia (156)
Series A (257)
Series B (203)
Service/supplier (11)
Sickle cell disease (105)
Special edition (27)
Spinal muscular atrophy (162)
Sponsored (43)
Startups (3806)
State (2)
Stomach cancer (19)
Supply chain (107)
Tariffs (85)
The Weekly (82)
Vaccines (1043)
Venture capital (96)
Weight loss (411)
Women's health (94)
Worklife (19)
Date
Today (101)
Last 7 days (544)
Last 30 days (2359)
Last 365 days (30733)
2026 (3974)
2025 (31063)
2024 (36297)
2023 (41014)
2022 (52277)
2021 (56763)
2020 (54920)
2019 (47416)
2018 (35696)
2017 (33023)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (754)
Alabama (90)
Alaska (7)
Arizona (319)
Arkansas (14)
Asia (40720)
Australia (6767)
California (11595)
Canada (3338)
China (1147)
Colorado (489)
Connecticut (503)
Delaware (342)
Europe (89311)
Florida (1716)
Georgia (363)
Hawaii (3)
Idaho (61)
Illinois (894)
India (69)
Indiana (530)
Iowa (24)
Japan (442)
Kansas (131)
Kentucky (41)
Louisiana (27)
Maine (72)
Maryland (1417)
Massachusetts (8421)
Michigan (330)
Minnesota (644)
Mississippi (5)
Missouri (130)
Montana (34)
Nebraska (28)
Nevada (122)
New Hampshire (83)
New Jersey (3083)
New Mexico (31)
New York (3041)
North Carolina (1550)
North Dakota (9)
Northern California (5648)
Ohio (340)
Oklahoma (21)
Oregon (45)
Pennsylvania (2327)
Puerto Rico (24)
Rhode Island (49)
South America (1122)
South Carolina (66)
South Dakota (1)
Southern California (4500)
Tennessee (178)
Texas (1781)
United States (41249)
Utah (343)
Vermont (1)
Virginia (272)
Washington D.C. (82)
Washington State (961)
West Virginia (4)
Wisconsin (116)
Wyoming (2)
738,749 Results for "poseida therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mergers & acquisitions
Roche Nears Completion of Poseida Acquisition Worth Up to $1.5B
In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.
January 8, 2025
·
3 min read
·
Tristan Manalac
Press Releases
Roche purchases shares in tender offer for Poseida Therapeutics, Inc.
January 8, 2025
·
5 min read
Biotech Beach
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
Poseida Therapeutics, Inc. announced that its virtual Annual Meeting of Stockholders will be held on Monday, June 17, 2024 at 1:00 p.m. PT.
June 3, 2024
·
2 min read
Press Releases
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
November 26, 2024
·
9 min read
Business
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
14 min read
Business
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
May 1, 2024
·
8 min read
Business
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.
March 25, 2024
·
5 min read
Biotech Beach
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 01, 2024
Poseida Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company’s new Chief Medical Officer.
April 1, 2024
·
2 min read
Press Releases
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
November 12, 2024
·
1 min read
Business
Astellas and Poseida Therapeutics Announce Strategic Investment to Support Poseida’s Commitment to Redefining Cancer Cell Therapy
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, “Poseida”) today announced a strategic investment to support the advancement of Poseida’s commitment to redefining cancer cell therapy.
August 7, 2023
·
8 min read
1 of 73,875
Next
